On 22 July 2025, OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies announced a public takeover offer to the shareholders of Integrum to tender all their shares, irrespective of share class at a price of SEK 44 in cash per share, which values all outstanding shares in Integrum at approximately SEK 939 million.

Which values all outstanding shares in Integrum at approximately SEK 939 million.

The Board member Rickard Brånemark has, due to his commitment to accept the offer, which means that a conflict of interest exists in accordance with section II.18 of the Takeover Rules, not participated and will not participate in the board’s handling of or decisions on matters related to the offer. Instead, an independent bid committee has been established, consisting of the other seven board members Bengt Sjöholm, Karin Wingstrand, Cecilia Wikström, Andrew Christensen, Scott Flora, Kristoffer Westergren, and Anette Lindqvist. Kristofer Westergren is the chairman of the bid committee.

The independent bid committee recommends Integrum’s shareholders to accept the offer.

“After an extensive evaluation, the independent bid committee believes that the offer not only represents a historically high bid premium and provides an attractive value for Integrum’s shareholders, but also brings together two operations that greatly complement each other. We have also taken into account the interests of other potential bidders and analyzed the offer against other financial alternatives and concluded that the offer, corresponding to a value of approximately SEK 939 million, is the most advantageous for Integrum’s shareholders,” says Kristofer Westergren, Chair of the independent bid committee.

There are currently no decisions on any material changes to Integrum’s or OsteoCentric’s employees and management or to the existing organization and operations, including the terms of employment and locations of the business.

Regarding the impact on the company, particularly with respect to employment, as well as strategic plans and the effects such plans may be expected to have on employment and on the locations, the bidder has stated the following:

“OsteoCentric highly values the skills and talents of Integrum’s management and employees as key elements of the company. Given OsteoCentric’s current knowledge of Integrum and in light of current market conditions, OsteoCentric does not intend to materially alter the operations of Integrum following the implementation of the offer. There are currently no decisions on any material changes to Integrum’s or OsteoCentric’s employees and management or to the existing organization and operations, including the terms of employment and locations of the business.”